Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 1.00 |
| ▸ | HTR3A | P46098 | 10/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.62 |
| ▸ | HTR3B | O95264 | 3/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695094 | 0.85 | HRH4 (0.74) | HRH4HTR3AHRH3KDM4EHTR3E | |
| SCHEMBL5780238 | 0.84 | HTR3A (0.72) | HRH4HTR3AHRH3HTR3EHTR3B | |
| SCHEMBL29293410 | 0.84 | HTR3A (0.72) | HRH4HTR3AHRH3HTR3EHTR3B | |
| SCHEMBL13648823 | 0.84 | HTR3A (0.72) | HRH4HTR3AHRH3KDM4EHTR3E | |
| SCHEMBL20651331 | 0.83 | HRH4 (0.70) | HRH4HTR3AHRH3KDM4EHTR3E | |
| SCHEMBL5780233 | 0.83 | HTR3A (0.70) | HRH4HTR3AHRH3KDM4EHTR3E | |
| Hydrochloric Acid SCHEMBL3970703 | 0.82 | HRH4 (0.70) | HRH4HTR3AHRH3KDM4EHTR3E | |
| SCHEMBL21154479 | 0.81 | HTR3A (0.68) | HRH4HTR3AHRH3KDM4EHTR3E | |
| SCHEMBL21864821 | 0.81 | HTR3A (0.68) | HRH4HTR3AHRH3KDM4EHTR3E | |
| SCHEMBL1500715 | 0.81 | HRH4 (0.68) | HRH4HTR3AHRH3KDM4EHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | claimed |
| EP-2044027-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-04-08 | — | — | EP | claimed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2858647-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2015-04-15 | — | — | EP | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013182711-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2013-12-12 | — | — | WO | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| EP-2044027-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 137/4885HRH3 2/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | HRH4 29/4885HTR3A 1946/4885HRH3 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.